[{"id":"8bfe55fa-807a-462e-8516-57ad53545259","acronym":"TWT-203","url":"https://clinicaltrials.gov/study/NCT05251714","created_at":"2022-02-23T20:55:03.056Z","updated_at":"2024-07-02T16:35:10.254Z","phase":"Phase 1/2","brief_title":"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer","source_id_and_acronym":"NCT05251714 - TWT-203","lead_sponsor":"Treadwell Therapeutics, Inc","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • luvixasertib (CFI-402257)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 05/27/2022","start_date":" 05/27/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-04-10"},{"id":"3ca48c09-60d2-4746-959e-d0335c8c0b2e","acronym":"CFI-402257-CL-001","url":"https://clinicaltrials.gov/study/NCT02792465","created_at":"2021-01-18T13:42:27.405Z","updated_at":"2024-07-02T16:35:23.139Z","phase":"Phase 1","brief_title":"A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT02792465 - CFI-402257-CL-001","lead_sponsor":"University Health Network, Toronto","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • luvixasertib (CFI-402257)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 11/11/2016","start_date":" 11/11/2016","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-01-17"}]